[Septic shock due to community-acquired complicated intra-abdominal infection treated with ertapenem: outcome in 25 cases].
OBJECTIVE
To assess the effectiveness of ertapenem in patients admitted to a surgical intensive care unit with septic shock due to community-acquired complicated intra-abdominal infection.


METHODS
Patients undergoing emergency surgery for community-acquired complicated intra-abdominal infection were enrolled prospectively. All patients were given intravenous ertapenem at a rate of 1 g/24 h and the guidelines of the Surviving Sepsis Campaign were applied. Outcome measures were duration of antibiotic therapy, mean length of stay in the surgical intensive care unit (ICU), antibiotic failure, and death while in the surgical ICU.


RESULTS
Twenty-five patients with a mean (SD) age of 74 (14) years were enrolled. The origin of infection was the colon in 56% of the cases; most patients (76%) had generalized peritonitis. The mean stay in the surgical ICU was 10 (7) days. The mean duration of antibiotic therapy was 5.8 (1.26) days. Antibiotic failure occurred in 12%. Mortality in the surgical ICU was 28%.


CONCLUSIONS
Our findings suggest that patients with community-acquired intra-abdominal infection and septic shock have a good chance of survival when treated according to the guidelines of the Surviving Sepsis Campaign. Ertapenem seems to give good results when used in this setting.
Maseda
E
E
Servicio de Anestesiología y Reanimación, Hospital Universitario La Paz, Madrid. emilio.maseda@gmail.com
Lillo
M
M
Fernández
L
L
Villagrán
M J
MJ
Gómez-Rice
A
A
Ramasco
F
F
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D017714:Community-Acquired Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D003422:Critical Care / Q000706:statistics & numerical data; D004630:Emergencies; D000077727:Ertapenem; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D007416:Intestinal Perforation / Q000150:complications; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D011446:Prospective Studies; D012772:Shock, Septic / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome; D047090:beta-Lactams / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D000077727:Ertapenem